Results 21 to 30 of about 786,143 (326)

Polysaccharide-based self-assembling nanohydrogels: An overview on 25-years research on pullulan [PDF]

, 2015
The aim of this overview is to review the evolution of the studies carried out, during more than 25 years, on nanohydrogels obtained by self-assembling of pullulan (PUL) using several hydrophobization strategies.
ALHAIQUE, Franco, COVIELLO, Tommasina, DI MEO, Chiara, MATRICARDI, PIETRO, MONTANARI, ELITA   +4 more
core   +1 more source

Polyvalent pneumococcal polysaccharide vaccines [PDF]

Journal of Infection, 1979
A 14-valent pneumococcal vaccine has recently been licensed for general use after extensive testing in human subjects. Antibody production was satisfactory in 92% of individuals and a highly significant (76-92%) reduction was found in the rates for pneumococcal pneumonias caused by the capsular types present in the vaccine. Children over 2 years of age
Philip P. Vella, Arlene A. McLean, A. F. Woodhour, Maurice R. Hilleman, Robert E. Weibel   +4 more
openaire   +3 more sources

Carrier Proteins Facilitate the Generation of Antipolysaccharide Immunity via Multiple Mechanisms

mBio, 2022
Capsular polysaccharides (CPSs) are important antigenic targets against bacterial infections. As T-independent antigens, however, CPSs elicit short-lived immune responses in adults and are poorly immunogenic in young children.
Fan Zhang, Claudette Thompson, Nicole Ma, Ying-Jie Lu, Richard Malley   +4 more
doaj   +1 more source

Longitudinal multiparameter single-cell analysis of macaques immunized with pneumococcal protein-conjugated or unconjugated polysaccharide vaccines reveals distinct antigen specific memory B cell repertoires.

PLoS ONE, 2017
BackgroundThe efficacy of protein-conjugated pneumococcal polysaccharide vaccines has been well characterized for children. The level of protection conferred by unconjugated polysaccharide vaccines remains less clear, particularly for elderly individuals
Bin Jia, Lisa K McNeil, Christopher D Dupont, Konstantinos Tsioris, Rachel M Barry, Ingrid L Scully, Adebola O Ogunniyi, Christopher Gonzalez, Michael W Pride, Todd M Gierahn, Paul A Liberator, Kathrin U Jansen, J Christopher Love   +12 more
doaj   +1 more source

Reduction of free polysaccharide contamination in the production of a 15-valent pneumococcal conjugate vaccine.

PLoS ONE, 2020
Glycoconjugate vaccines are vaccines in which a bacterial polysaccharide antigen is conjugated to a carrier protein to enhance immunogenicity by promoting T cell-dependent immune response. However, the free (unreacted) polysaccharides remaining after the
Yoon Hee Whang, Soo Kyung Kim, Hyeseon Yoon, Seuk Keun Choi, Yeong Ok Baik, Chankyu Lee, Inhwan Lee   +6 more
doaj   +1 more source

A universal UHPLC-CAD platform for the quantification of polysaccharide antigens

Scientific Reports, 2023
Several glycoconjugate-based vaccines against bacterial infections have been developed and licensed for human use. Polysaccharide (PS) analysis and characterization is therefore critical to profile the composition of polysaccharide-based vaccines. For PS
A. Corrado, M. De Martino, V. Bordoni, S. Giannini, F. Rech, S. Cianetti, F. Berti, C. Magagnoli, R. De Ricco   +8 more
doaj   +1 more source

Polysaccharide pneumococcal vaccines

BMJ, 2002
Infection with Streptococcus pneumoniae (pneumococcus) is a leading cause of illness in young children and of illness and death in elderly people and people with immune deficiencies and chronic illness. Pneumococcus causes a spectrum of disease: infections of the upper respiratory tract, otitis media, invasive infections such as bacteraemia and ...
Vittorio Demicheli, Tom Jefferson
openaire   +4 more sources

PROTEINS AND OTHER CARRIERS FOR CREATION OF CONJUGATED VACCINES: PROPERTIES AND APPLICATION

Журнал микробиологии, эпидемиологии и иммунобиологии, 2016
Vaccination is a key element in prophylaxis of infectious diseases. Effective vaccines based on polysaccharide capsules were developed for a number of microorganisms. Effectiveness of polysaccharides as antigens, however, is low in the main risk groups -
L. A. Lisitskaya, A. V. Kolesnikov, A. V. Kozyr, I. G. Shemyakin, A. K. Ryabko, O. N. Krasavtseva, LA. .. Dyatlov   +6 more
doaj   +1 more source

A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. [PDF]

, 2010
BACKGROUND: Streptococcus pneumoniae is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa.
French, N, Gilks, CF, Gordon, SB, Longwe, H, Molyneux, ME, Mwafulirwa, G, Mwaiponya, M, Mwalukomo, T, White, SA, Zijlstra, EE   +9 more
core   +2 more sources

SEROTYPE-INDEPENDENT VACCINES AGAINST PNEUMOCOCCAL INFECTION

Журнал микробиологии, эпидемиологии и иммунобиологии, 2016
Creation of serotype-independent vaccines includes 4 directions - construction of protein vaccines based on recombinant pneumococcus proteins, whole-cell killed or attenuated vaccines, DNA-vaccines and use of Streptococcus pneumoniae as a carrier for ...
I. B. Semenova, N. A. Mikhailova
doaj   +1 more source